David E. Barker

1.5k total citations
19 papers, 1.0k citations indexed

About

David E. Barker is a scholar working on Virology, Infectious Diseases and Epidemiology. According to data from OpenAlex, David E. Barker has authored 19 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Virology, 8 papers in Infectious Diseases and 7 papers in Epidemiology. Recurrent topics in David E. Barker's work include HIV Research and Treatment (6 papers), HIV/AIDS Research and Interventions (5 papers) and Herpesvirus Infections and Treatments (4 papers). David E. Barker is often cited by papers focused on HIV Research and Treatment (6 papers), HIV/AIDS Research and Interventions (5 papers) and Herpesvirus Infections and Treatments (4 papers). David E. Barker collaborates with scholars based in United States, Switzerland and Italy. David E. Barker's co-authors include Bernard Roizman, Christina M. Marra, Sheila A. Lukehart, Judith L. Nerad, Anne Rompalo, Charles Raines, James J. Corbett, Molly E. Eaton, Stacy L. Smith and Bradley P. Stoner and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Journal of Virology.

In The Last Decade

David E. Barker

19 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David E. Barker United States 14 483 327 256 251 212 19 1.0k
Kenneth F. Wagner United States 14 405 0.8× 370 1.1× 194 0.8× 310 1.2× 156 0.7× 32 1.2k
Jennifer M. Best United Kingdom 23 1.1k 2.3× 152 0.5× 345 1.3× 81 0.3× 65 0.3× 59 1.5k
Séverine Mercier‐Delarue France 17 335 0.7× 68 0.2× 456 1.8× 91 0.4× 293 1.4× 48 905
Michael Remington United States 16 1.2k 2.5× 66 0.2× 327 1.3× 165 0.7× 216 1.0× 20 1.5k
Kihei Terada Japan 18 714 1.5× 49 0.1× 109 0.4× 284 1.1× 64 0.3× 57 995
Pentti Ukkonen Finland 18 599 1.2× 69 0.2× 300 1.2× 147 0.6× 44 0.2× 36 1.1k
J. M. Best United Kingdom 17 726 1.5× 146 0.4× 233 0.9× 38 0.2× 78 0.4× 35 875
James F. Papin United States 19 488 1.0× 53 0.2× 367 1.4× 221 0.9× 33 0.2× 42 988
Thomas L. Cherpes United States 22 924 1.9× 232 0.7× 144 0.6× 1.1k 4.4× 81 0.4× 48 1.9k
Mauricio Vargas‐Cortes United States 8 709 1.5× 41 0.1× 183 0.7× 105 0.4× 105 0.5× 17 980

Countries citing papers authored by David E. Barker

Since Specialization
Citations

This map shows the geographic impact of David E. Barker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Barker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Barker more than expected).

Fields of papers citing papers by David E. Barker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Barker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Barker. The network helps show where David E. Barker may publish in the future.

Co-authorship network of co-authors of David E. Barker

This figure shows the co-authorship network connecting the top 25 collaborators of David E. Barker. A scholar is included among the top collaborators of David E. Barker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David E. Barker. David E. Barker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Elmeliegy, Mohamed, et al.. (2015). 307 Population pharmacokinetic and pharmacodynamic modeling of bevacizumab and a proposed biosimilar (GP2019) in healthy male volunteers. European Journal of Cancer. 51. S56–S57. 1 indexed citations
3.
Hotton, Anna, et al.. (2014). Transmission Clustering Among Newly Diagnosed HIV Patients in Chicago, 2008 to 2011. JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(1). 46–54. 39 indexed citations
4.
Hodowanec, Aimee, et al.. (2012). Thalidomide-Associated Thrombosis in the Treatment of HIV-Associated Severe Aphthous Disease. Journal of the International Association of Physicians in AIDS Care. 11(6). 345–347. 2 indexed citations
5.
Skiest, Daniel J., Calvin Cohen, Karam Mounzer, et al.. (2011). Similar Efficacy of Raltegravir When Used With or Without a Protease Inhibitor in Treatment-Experienced Patients. HIV Clinical Trials. 12(3). 131–140. 5 indexed citations
6.
7.
Huhn, Gregory, Sheila Badri, Frank Tverdek, et al.. (2010). Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution. AIDS Research and Therapy. 7(1). 44–44. 16 indexed citations
8.
Hota, Bala, et al.. (2009). Reliability at the Lower Limits of HIV-1 RNA Quantification in Clinical Samples: A Comparison of RT-PCR versus bDNA Assays. PLoS ONE. 4(6). e6008–e6008. 13 indexed citations
9.
Badri, Sheila, et al.. (2007). Utility of Repeat Genotypic Resistance Testing and Clinical Response in Patients with Three Class Resistance and Virologic Treatment Failure. AIDS Patient Care and STDs. 21(8). 544–550. 5 indexed citations
10.
Marra, Christina M., Clare Maxwell, Stacy L. Smith, et al.. (2004). Cerebrospinal Fluid Abnormalities in Patients with Syphilis: Association with Clinical and Laboratory Features. The Journal of Infectious Diseases. 189(3). 369–376. 333 indexed citations
11.
Badri, Sheila, et al.. (2003). How Does Expert Advice Impact Genotypic Resistance Testing in Clinical Practice?. Clinical Infectious Diseases. 37(5). 708–713. 13 indexed citations
12.
Marra, Christina M., Natasa Rajicic, David E. Barker, et al.. (2002). A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS. 16(13). 1791–1797. 143 indexed citations
13.
14.
Ward, P L, David E. Barker, & Bernard Roizman. (1996). A novel herpes simplex virus 1 gene, UL43.5, maps antisense to the UL43 gene and encodes a protein which colocalizes in nuclear structures with capsid proteins. Journal of Virology. 70(5). 2684–2690. 30 indexed citations
15.
Barker, David E.. (1995). Use of Thallium-201 Brain SPECT to Differentiate Cerebral Lymphoma from Toxoplasma Encephalitis in AIDS Patients. Infectious Diseases in Clinical Practice. 4(4). 284–284. 44 indexed citations
16.
Barker, David E.. (1995). Survival Factors in Rhino-Orbital-Cerebral Mucormycosis. Infectious Diseases in Clinical Practice. 4(3). 182–182. 21 indexed citations
17.
Barker, David E. & Bernard Roizman. (1992). The unique sequence of the herpes simplex virus 1 L component contains an additional translated open reading frame designated UL49.5. Journal of Virology. 66(1). 562–566. 49 indexed citations
18.
Campadelli‐Fiume, Gabriella, et al.. (1990). Glycoprotein C-dependent attachment of herpes simplex virus to susceptible cells leading to productive infection. Virology. 178(1). 213–222. 53 indexed citations
19.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenneth F. Wagner Breakdown of academic impact, for papers by Jennifer M. Best Breakdown of academic impact, for papers by Séverine Mercier‐Delarue Breakdown of academic impact, for papers by Michael Remington Breakdown of academic impact, for papers by Kihei Terada Breakdown of academic impact, for papers by Pentti Ukkonen Breakdown of academic impact, for papers by J. M. Best Breakdown of academic impact, for papers by James F. Papin Breakdown of academic impact, for papers by Thomas L. Cherpes Breakdown of academic impact, for papers by Mauricio Vargas‐Cortes
Rankless by CCL
2026